Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Brian Seal

Showing results (31-40 of 58) with videos related to

Pageof 6
Sort By:
The Oncologist|March 11, 2022
Real-world Treatment Patterns and Reasons for Therapy Selection in Patients with Advanced Hepatocellular Carcinoma in US Oncology PracticesAndrew J Klink, Landon Z Marshall, Abdalla Aly, et al.
Value in Health : the Journal of the International Society for Pharmacoeconomics and Outcomes Research|August 17, 2013
Transarterial chemoembolization treatment: association between multiple treatments, cumulative expenditures, and survivalIan M Breunig, Fadia T Shaya, Nader Hanna, et al.
American Journal of Clinical Oncology|September 26, 2013
Multispecialist Care and Mortality in Hepatocellular CarcinomaViktor V Chirikov, C Daniel Mullins, Nader Hanna, et al.
BMC Cancer|April 7, 2020
Long-term survival trends in patients with unresectable stage III non-small cell lung cancer receiving chemotherapy and radiation therapy: a SEER cancer registry analysisRyan N Hansen, Yiduo Zhang, Brian Seal, et al.
Journal of Occupational and Environmental Medicine|January 1, 2010
The cost of poor sleep: workplace productivity loss and associated costsMark R Rosekind, Kevin B Gregory, Melissa M Mallis, et al.
General Dentistry|November 11, 2010
Adverse events and intravenous versus oral bisphosphonate use in patients with osteoporosis and cancer in the U.SGrant H Skrepnek, Brian Seal, Muralikrishna Tangirala, et al.
Journal of the American Geriatrics Society|April 2, 2011
Chemotherapy treatment and survival in older women with estrogen receptor-negative metastatic breast cancer: a population-based analysisMyra Schneider, Ilene H Zuckerman, Eberechukwu Onukwugha, et al.
Pharmacoeconomics|December 3, 2013
Comparative and cost effectiveness of treatment modalities for hepatocellular carcinoma in SEER-MedicareFadia T Shaya, Ian M Breunig, Brian Seal, et al.
The Journal of Allergy and Clinical Immunology|March 4, 2008
Asthma costs and utilization in a managed care organizationRobert S Zeiger, Joel W Hay, Richard Contreras, et al.
Leukemia & Lymphoma|October 3, 2018
Adverse events, resource use, and economic burden associated with mantle cell lymphoma: a real-world assessment of privately insured patients in the United StatesRavi K Goyal, Saurabh P Nagar, Shaum M Kabadi, et al.
Pageof 6

Showing results (31-40 of 58) with videos related to

Sort By:
Pageof 6
The Oncologist|March 11, 2022
Real-world Treatment Patterns and Reasons for Therapy Selection in Patients with Advanced Hepatocellular Carcinoma in US Oncology PracticesAndrew J Klink, Landon Z Marshall, Abdalla Aly, et al.
Value in Health : the Journal of the International Society for Pharmacoeconomics and Outcomes Research|August 17, 2013
Transarterial chemoembolization treatment: association between multiple treatments, cumulative expenditures, and survivalIan M Breunig, Fadia T Shaya, Nader Hanna, et al.
American Journal of Clinical Oncology|September 26, 2013
Multispecialist Care and Mortality in Hepatocellular CarcinomaViktor V Chirikov, C Daniel Mullins, Nader Hanna, et al.
BMC Cancer|April 7, 2020
Long-term survival trends in patients with unresectable stage III non-small cell lung cancer receiving chemotherapy and radiation therapy: a SEER cancer registry analysisRyan N Hansen, Yiduo Zhang, Brian Seal, et al.
Journal of Occupational and Environmental Medicine|January 1, 2010
The cost of poor sleep: workplace productivity loss and associated costsMark R Rosekind, Kevin B Gregory, Melissa M Mallis, et al.
General Dentistry|November 11, 2010
Adverse events and intravenous versus oral bisphosphonate use in patients with osteoporosis and cancer in the U.SGrant H Skrepnek, Brian Seal, Muralikrishna Tangirala, et al.
Journal of the American Geriatrics Society|April 2, 2011
Chemotherapy treatment and survival in older women with estrogen receptor-negative metastatic breast cancer: a population-based analysisMyra Schneider, Ilene H Zuckerman, Eberechukwu Onukwugha, et al.
Pharmacoeconomics|December 3, 2013
Comparative and cost effectiveness of treatment modalities for hepatocellular carcinoma in SEER-MedicareFadia T Shaya, Ian M Breunig, Brian Seal, et al.
The Journal of Allergy and Clinical Immunology|March 4, 2008
Asthma costs and utilization in a managed care organizationRobert S Zeiger, Joel W Hay, Richard Contreras, et al.
Leukemia & Lymphoma|October 3, 2018
Adverse events, resource use, and economic burden associated with mantle cell lymphoma: a real-world assessment of privately insured patients in the United StatesRavi K Goyal, Saurabh P Nagar, Shaum M Kabadi, et al.
Pageof 6